Depomed buys Janssen's Nucynta analgesics for $1.1B

Depomed Inc. (NASDAQ:DEPO) acquired U.S. rights to the Nucynta tapentadol analgesic franchise from the Janssen Pharmaceuticals Inc. unit

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE